You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):丁二酸復瑞替尼膠囊用於治療非小細胞肺癌(ALK+)啟動III期臨牀試驗
格隆匯 01-19 22:27

格隆匯1月19日丨復星醫藥(02196.HK)公吿,近日,上海復星醫藥(集團)股份有限公司(以下簡稱“公司”)控股子公司江蘇萬邦生化醫藥集團有限責任公司(以下簡稱“江蘇萬邦”)於中國境內(不包括港澳台,下同)就丁二酸復瑞替尼膠囊(原項目代號SAF-189,以下簡稱“該新藥”)用於治療非小細胞肺癌(ALK+)啟動III期臨牀試驗。

該新藥為創新型小分子化學藥物,擬主要用於腫瘤治療。該新藥由本公司控股子公司重慶復創醫藥研究有限公司與中國科學院上海藥物研究所共同進行臨牀前研究,並獨家許可江蘇萬邦就該新藥於中國境內進行獨家開發(包括但不限於臨牀試驗、上市註冊等)和商業化。

截至公吿日,於中國境內上市的針對非小細胞肺癌(ALK+)的藥品主要包括PriferInc.的克唑替尼膠囊、NovartisAG的塞瑞替尼膠囊、貝達藥業股份有限公司的鹽酸恩沙替尼膠囊及Roche的鹽酸阿來替尼膠囊。根據IQVIACHPA資料(由IQVIA提供,IQVIA是全球領先的醫藥健康產業專業信息和戰略諮詢服務提供商;IQVIACHPA數據代表中國境內100張牀位以上的醫院藥品銷售市場,不同的藥品因其各自銷售渠道佈局的不同,實際銷售情況可能與IQVIACHPA數據存在不同程度的差異),2020年度及2021年上半年,該等藥品於中國境內的銷售額分別約為人民幣18.25億元、11.45億元。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account